|
Importantly, consistent and complete B cell depletion was observed in all patients within the first month of the CAR-T infusion.
There were no safety or side-effect issues in any of the myositis patients. The administration of CAR-T infusion was well tolerated.
Two of the three patients with follow-up beyond three months demonstrated a reduction in disease-associated antibodies.
The Cabaletta Bio results follow earlier case studies from Dr. Rebecca Nicolai, also shared at the conference but which we reported to JM families back in September. Dr. Nicolai and her colleagues have successfully treated two adolescents with difficult-to-treat JM—a 12-year-old boy and a 13-year-old girl—with CAR-T therapies. Both children had been previously unresponsive to standard treatments.
Dr. Nicolai reports that the first JM patient achieved sustained B cell depletion and ongoing immunosuppressive drug-free clinical and radiologic improvement eight months after a single CAR-T infusion. This included remarkable improvement of the boy’s severe calcinosis.
Recently, colleagues of Dr. Nicolai completed CAR-T therapy with the aforementioned 13-year-old girl. Within weeks, she showed drastic improvements in her overall condition, including the elimination of calcium deposits all over her body.
As a partner with Cure JM, Cabaletta’s goal is to achieve “drug-free, symptom-free, sustained remission” of juvenile myositis and other inflammatory myopathies, as noted by CEO and founder Dr. Steven Nichtberger. “CAR-T has the potential to deliver compelling disease responses without the need for chronic, immunosuppressive therapy. Early results indicate that myositis and related autoimmune diseases have been halted in their tracks.”
If you are attending the Cure JM Family Conference next June in Chicago, you will have the opportunity to meet and discuss CAR-T with Dr. Nicolai and Dr. Chang. Both will be presenting and participating in a panel discussion on the promise of CAR-T as a curative therapy in juvenile myositis as longer-term data is assessed.
JM patients age 18+ can already apply to participate in the trial, you can learn more about this trial here. We expect trial enrollment for pediatric patients to start in early 2025. Several Cure JM Clinical Care Network partner hospitals in the East, Midwest, and West will be serving as trial sites.
This compelling life-changing progress wouldn't be possible without your support. Thank you for helping us get this far.
Our work, however, is far from done, and we need your help to move this life-changing work forward. The Coffey Family Match will match your donation, doubling the impact of your support. Every dollar brings us closer to a future free of juvenile myositis, where children can pursue their dreams without limits.
Like most rare diseases, progress is only made possible by you, your friends, and your family, who care about our children battling this life-altering disease.
Thank you for your unwavering commitment to making a world free of juvenile myositis possible for our children. Your gift today will be put right to work to advance CAR-T's life-changing potential.
|